Have a feature idea you'd love to see implemented?
Let us know!
ARCT Arcturus Therapeutics Holdings Inc
Price (delayed)
$16.91
Market cap
$458.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
$191.86M
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™
Highlights
Arcturus Therapeutics Holdings's debt has decreased by 45% YoY and by 3.6% QoQ
ARCT's quick ratio is up by 25% since the previous quarter and by 6% year-on-year
The net income has dropped by 163% year-on-year but it is up by 13% since the previous quarter
The company's EPS has shrunk by 162% YoY but it rose by 13% QoQ
Arcturus Therapeutics Holdings's gross profit has decreased by 46% YoY and by 2.1% QoQ
The revenue has declined by 46% year-on-year and by 2.1% since the previous quarter
Key stats
What are the main financial stats of ARCT
Market
Valuations
Earnings
Shares outstanding
27.09M
Market cap
$458.05M
Enterprise value
$191.86M
Price to book (P/B)
1.75
Price to sales (P/S)
2.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
Revenue
$160.4M
EBIT
-$69.26M
EBITDA
-$65.72M
Free cash flow
-$61.62M
Per share
Balance sheet
Liquidity
EPS
-$2.34
Free cash flow per share
-$2.28
Book value per share
$9.68
Revenue per share
$5.93
TBVPS
$13.7
Total assets
$370.65M
Total liabilities
$108.79M
Debt
$25.99M
Equity
$261.87M
Working capital
$261.36M
Debt to equity
0.1
Current ratio
4.76
Quick ratio
4.64
Net debt/EBITDA
4.05
Margins
Efficiency
Dividend
EBITDA margin
-41%
Gross margin
100%
Net margin
-39.1%
Operating margin
-50.2%
Return on assets
-15.6%
Return on equity
-23.6%
Return on invested capital
-481.7%
Return on capital employed
-23%
Return on sales
-43.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARCT stock price
How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-0.94%
1 week
5.56%
1 month
-14.55%
1 year
-28.13%
YTD
-46.37%
QTD
-27.14%
Financial performance
How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$160.4M
Gross profit
$160.4M
Operating income
-$80.55M
Net income
-$62.64M
Gross margin
100%
Net margin
-39.1%
The net income has dropped by 163% year-on-year but it is up by 13% since the previous quarter
Arcturus Therapeutics Holdings's gross profit has decreased by 46% YoY and by 2.1% QoQ
The revenue has declined by 46% year-on-year and by 2.1% since the previous quarter
Arcturus Therapeutics Holdings's net margin has increased by 11% QoQ
Growth
What is Arcturus Therapeutics Holdings's growth rate over time
Valuation
What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
1.75
P/S
2.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
The company's EPS has shrunk by 162% YoY but it rose by 13% QoQ
ARCT's P/B is 56% lower than its 5-year quarterly average of 4.0 and 40% lower than its last 4 quarters average of 2.9
ARCT's equity is down by 6% year-on-year
ARCT's price to sales (P/S) is 93% lower than its 5-year quarterly average of 41.0 and 44% lower than its last 4 quarters average of 5.1
The revenue has declined by 46% year-on-year and by 2.1% since the previous quarter
Efficiency
How efficient is Arcturus Therapeutics Holdings business performance
The ROA has shrunk by 171% YoY but it has increased by 8% QoQ
The company's return on equity has shrunk by 169% YoY but it rose by 11% QoQ
Arcturus Therapeutics Holdings's ROIC has decreased by 44% from the previous quarter
The company's return on sales rose by 9% QoQ
Dividends
What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARCT.
Financial health
How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total liabilities has decreased by 39% YoY and by 16% QoQ
ARCT's current ratio is up by 26% QoQ and by 6% YoY
Arcturus Therapeutics Holdings's debt is 90% lower than its equity
Arcturus Therapeutics Holdings's debt has decreased by 45% YoY and by 3.6% QoQ
The debt to equity has decreased by 41% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.